Method and pharmaceutical composition for treating cancer

Patent metadata

Field	Value
Publication number	US-11149271-B2
Application number	US-201816120606-A
Country	US
Kind code	B2
Filing date	Sep 4, 2018
Priority date	Sep 4, 2018
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

A method of treating a subject suffering from cancer includes administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule is isolated or derived from a plant of the genus Taxus . A method of inhibiting growth or proliferation of cancer cells includes contacting cancer cells with the RNA molecule; and a pharmaceutical composition for treating cancer includes the RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector include the double-stranded RNA molecule.

First claim

The invention claimed is:

1. A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule comprises a sense sequence selected from SEQ ID NO: 1 to SEQ ID NO: 100 and a complementary antisense sequence.

2. The method of claim 1 , wherein the RNA molecule further comprises 2 mer 3′ overhangs.

3. The method of claim 1 , wherein the sense sequence is selected from SEQ ID NO: 1 to SEQ ID NO: 36.

4. The method of claim 1 , wherein the RNA molecule comprises at least one modified nucleoside selected from inosine, 1-methyladenosine, 2-methyladenosine, N 6 -m ethyladenosine, N 6 -isopentenyladenosine, 2′-O-methyladenosine, N 6 -acetyladenosine, 1-methylinosine, pseudouridine, dihydrouridine, or 2-methylthio-N 6 -methyladenosine.

5. The method of claim 1 , wherein the cancer is ovarian cancer, liver cancer, breast cancer, colorectal cancer, or lung cancer.

6. The method of claim 1 , wherein the cancer is resistant against Taxol.

7. The method of claim 1 , wherein the RNA molecule is isolated or derived from Taxus chinensis (Pilger) Rehd. var. mairei.

8. The method of claim 1 , wherein the step of administering the RNA molecule to the subject comprises contacting cancer cells of the subject with the RNA molecule.

9. A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule comprises a sequence selected from SEQ ID NO: 201 to SEQ ID NO: 225.

10. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with an effective amount of a RNA molecule, wherein the RNA molecule comprises a sense sequence selected from SEQ ID NO: 1 to SEQ ID NO: 100 and a complementary antisense sequence.

11. The method of claim 10 , wherein the RNA molecule further comprises 2 mer 3′ overhangs.

12. The method of claim 10 , wherein the sense sequence is selected from SEQ ID NO: 1 to SEQ ID NO: 36.

13. The method of claim 10 , wherein the RNA molecule comprises at least one modified nucleoside selected from inosine, 1-methyladenosine, 2-methyladenosine, N 6 -methyladenosine, N 6 -isopentenyladenosine, 2′-O-methyladenosine, acetyladenosine, 1-methylinosine, pseudouridine, dihydrouridine, or 2-methylthio-N 6 -methyladenosine.

14. The method of claim 10 , wherein the cancer cells are ovarian cancer cells, liver cancer cells, breast cancer cells, colorectal cancer cells, or lung cancer cells.

15. The method of claim 10 , wherein the cancer cells are resistant against Taxol.

16. The method of claim 10 , wherein the RNA molecule is isolated or derived from Taxus chinensis (Pilger) Rehd. var. mairei.

17. The method of claim 10 , wherein the RNA molecule is provided in a composition comprising a gene delivery carrier.

18. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with an effective amount of a RNA molecule, wherein the RNA molecule comprises a sequence selected from SEQ ID NO: 201 to SEQ ID NO: 225.

Assignees

• Univ Macau Sci & Tech

Inventors

• Jiang zhi-hong
• Yan Tong-Meng
• Cao Kai-Yue

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title